These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 31145289)

  • 1. Targeted therapy with anlotinib for patient with recurrent glioblastoma: A case report and literature review.
    Lv Y; Zhang J; Liu F; Song M; Hou Y; Liang N
    Medicine (Baltimore); 2019 May; 98(22):e15749. PubMed ID: 31145289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy with anlotinib for a leptomeningeal spread recurrent glioblastoma patient.
    Li C; Li W; Dai S; Sharma A; Sharma HS; Wu Y
    Prog Brain Res; 2021; 265():407-414. PubMed ID: 34560927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial.
    Lai S; Li P; Liu X; Liu G; Xie T; Zhang X; Wang X; Huang J; Tang Y; Liu Z; Shen G; Li C; Lu F; Wang L; Jiang F; Sun C; Chen Y; Chen M
    Cancer Biol Med; 2024 Mar; 21(5):433-44. PubMed ID: 38445445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma.
    Wang Y; Liang D; Chen J; Chen H; Fan R; Gao Y; Gao Y; Tao R; Zhang H
    Oncologist; 2021 Mar; 26(3):173-177. PubMed ID: 32949176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
    J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficiency of Anlotinib in Patients with Recurrent Grade 4 Glioma: A Single-Center Retrospective Analysis.
    Wang Q; Wei W; Ji X; Li J; Wu N; Li J; Sun K; Ma C; Pan H
    Neurol India; 2024 May; 72(3):578-584. PubMed ID: 39041976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anlotinib is effective in the treatment of advanced pancreatic cancer: a case report.
    Li S; Niu M; Deng W; Li N; Wei C; Luo S
    Anticancer Drugs; 2022 Jan; 33(1):e558-e561. PubMed ID: 34387586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: A case report.
    Zhang A; Liu B; Xu D; Sun Y
    Medicine (Baltimore); 2019 Dec; 98(52):e18435. PubMed ID: 31876723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report.
    Sun L; Yang M; Zhang X; Li H; Wu L; Zhang Y; Cai S
    Medicine (Baltimore); 2020 May; 99(20):e20053. PubMed ID: 32443311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.
    Kalpathy-Cramer J; Chandra V; Da X; Ou Y; Emblem KE; Muzikansky A; Cai X; Douw L; Evans JG; Dietrich J; Chi AS; Wen PY; Stufflebeam S; Rosen B; Duda DG; Jain RK; Batchelor TT; Gerstner ER
    J Neurooncol; 2017 Feb; 131(3):603-610. PubMed ID: 27853960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma.
    Xu Q; Huang K; Meng X; Weng Y; Zhang L; Bu L; Zheng X; Cai J; Zhan R; Chen Q
    Clin Cancer Res; 2023 Oct; 29(19):3859-3866. PubMed ID: 37477938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Penpulimab and anlotinib in an elderly patient with recurrent cervical cancer: a case report and literature review.
    Niu G; Wang H; Ren Y; Xing X; Zhao L; Liu N; Wen X; Zhai Y
    Immunotherapy; 2023 Aug; 15(12):905-912. PubMed ID: 37340883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
    Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
    Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rechallenging Recurrent Glioblastoma with Intra-Arterial Bevacizumab with Blood Brain-Barrier Disruption Results in Radiographic Response.
    Faltings L; Kulason KO; Patel NV; Wong T; Fralin S; Li M; Schneider JR; Filippi CG; Langer DJ; Ortiz R; Boockvar JA
    World Neurosurg; 2019 Nov; 131():234-241. PubMed ID: 31351210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
    DI Cristofori A; Carrabba G; Lanfranchi G; Menghetti C; Rampini P; Caroli M
    Anticancer Res; 2013 Aug; 33(8):3383-9. PubMed ID: 23898108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
    Liu J; Deng YT; Jiang Y
    Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of advanced ovarian cancer with anlotinib: a case report.
    Zhang P; Ma L; Wang X; Zhang R; Dong Y
    J Int Med Res; 2020 Dec; 48(12):300060520976824. PubMed ID: 33284728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy opens the blood-brain barrier and synergizes with anlotinib in treating glioblastoma.
    Li PJ; Lai SZ; Jin T; Ying HJ; Chen YM; Zhang P; Hang QQ; Deng H; Wang L; Feng JG; Chen XZ; Guo P; Chen M; Tian Y; Chen YY
    Radiother Oncol; 2023 Jun; 183():109633. PubMed ID: 36963438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway.
    Xu P; Wang H; Pan H; Chen J; Deng C
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):183-196. PubMed ID: 34997858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.